Medtronic Reshapes Portfolio With MiniMed IPO And Stealth AXiS Approval

Simply Wall St

Wed, February 25, 2026 at 11:12 AM GMT+9 4 min read

In this article:

MDT

-1.89%

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.

Medtronic (NYSE:MDT) plans to spin off its Diabetes segment through an IPO of its subsidiary MiniMed Group, creating a standalone business focused on diabetes care.

The company also received FDA clearance for its Stealth AXiS surgical system, a new platform for spine surgery.

At a share price of $96.75, Medtronic has a 1 year return of 10.3% and a 3 year return of 28.9%, while the 5 year return stands at a 4.7% decline. These figures present a mixed picture for long term holders as Medtronic reshapes its portfolio and concentrates on areas it identifies as priorities.

For you as an investor, the MiniMed IPO and the Stealth AXiS clearance could affect how Medtronic’s earnings mix, risk profile, and capital needs develop from here. The separation of the Diabetes unit and the introduction of new spine surgery technology may also influence how the market compares Medtronic with other large medtech peers over time.

Stay updated on the most important news stories for Medtronic by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Medtronic.

NYSE:MDT Earnings & Revenue Growth as at Feb 2026

We’ve flagged 1 risk for Medtronic. See which could impact your investment.

For Medtronic, separating the Diabetes segment via the MiniMed IPO and securing FDA clearance for the Stealth AXiS surgical system both point to a tighter focus on businesses where it sees the clearest payoff from capital and R&D. Spinning off Diabetes removes a complex, often lower margin area from the consolidated mix, which can make it easier for you to assess performance in core cardiovascular, neuroscience, and medical-surgical lines. At the same time, Stealth AXiS, with its integrated planning, navigation, robotics, and real time alignment tracking, aims to deepen Medtronic’s position in spine surgery against peers such as Johnson & Johnson, Stryker, and Zimmer Biomet. Taken together, these moves may shift the company toward higher margin, technology-heavy platforms while also changing how steady or cyclical earnings look over time.

How This Fits Into The Medtronic Narrative

The Stealth AXiS clearance aligns with the narrative’s focus on robotics, AI-enabled ecosystems, and procedure growth in areas like spine surgery, supporting the idea that product platforms can drive higher quality revenue.

The Diabetes spin off could complicate execution, which ties directly to the narrative’s concern that restructuring and segment transitions might pressure margins and earnings if they do not go to plan.

The IPO of MiniMed and the specific terms, capital structure, and any transition services between Medtronic and the new entity are not fully reflected in the existing narrative, yet these details could be important for future earnings mix.

 






Story Continues  

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Medtronic to help decide what it’s worth to you.

The Risks and Rewards Investors Should Consider

⚠️ Medtronic still carries a high level of debt, so the company’s capital allocation around the Diabetes spin off, IPO proceeds, and new technology investments could matter for financial flexibility.

⚠️ Spinning off Diabetes and ramping a complex system like Stealth AXiS adds execution and regulatory risk, particularly if adoption is slower than expected or transition costs weigh on margins.

🎁 Analysts highlight several rewards, including earnings growth expectations, support from Medtronic’s long record of dividend payments, and a P/E below the broader medical equipment industry, which may appeal to value focused investors.

🎁 The Stealth AXiS platform and broader AiBLE ecosystem extend Medtronic’s presence in high technology surgical tools, which could support procedure volumes and deepen relationships with hospitals and surgeons over time.

What To Watch Going Forward

From here, you may want to watch how Medtronic structures the MiniMed IPO, including any retained stake and the effect on reported margins, as well as how quickly Stealth AXiS moves from clearance to meaningful commercial uptake. Tracking whether revenue and earnings stay in line with the company’s fiscal 2026 guidance, and how management talks about fiscal 2027 after the spin off, will also help you judge whether this portfolio shift is translating into the business performance the market expects.

To ensure you’re always in the loop on how the latest news impacts the investment narrative for Medtronic, head to the community page for Medtronic to never miss an update on the top community narratives.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include MDT.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info